BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced financial results for the fourth quarter and full year 2016 and provided a corporate update.
“We began 2017 with great momentum, having achieved significant clinical and corporate milestones last year, particularly in the fourth quarter,” said Aimmune CEO Stephen Dilly, M.B.B.S., Ph.D. “In November 2016, we completed global enrollment of our ongoing Phase 3 PALISADE trial, which lays a strong foundation for our AR101 Phase 3 development program in peanut allergy. That same month, we also announced a strategic investment of $145 million by Nestlé Health Science while retaining full global rights to AR101 and our pipeline. As a result, we began 2017 in a strong financial position with approximately $283 million in cash and investments. Our resources and efforts in 2017 will continue to be focused largely on execution of our Phase 3 program for AR101. We continue to expect to have top-line data from PALISADE available around year-end 2017 and submit regulatory filings in the U.S. and Europe in late 2018. Our current capital resources fund us through these events.”
“We began 2017 with great momentum, having achieved significant clinical and corporate milestones last year, particularly in the fourth quarter,” said Aimmune CEO Stephen Dilly, M.B.B.S., Ph.D. “In November 2016, we completed global enrollment of our ongoing Phase 3 PALISADE trial, which lays a strong foundation for our AR101 Phase 3 development program in peanut allergy. That same month, we also announced a strategic investment of $145 million by Nestlé Health Science while retaining full global rights to AR101 and our pipeline. As a result, we began 2017 in a strong financial position with approximately $283 million in cash and investments. Our resources and efforts in 2017 will continue to be focused largely on execution of our Phase 3 program for AR101. We continue to expect to have top-line data from PALISADE available around year-end 2017 and submit regulatory filings in the U.S. and Europe in late 2018. Our current capital resources fund us through these events.”
